Buchumschlag

The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer

Weitere Versionen anzeigen (1)

Background: In various tumor entities, expression of cancer stem cell (CSC) antigens has been proven to be prognostically unfavorable. However, for lung cancer, the data are scant and conflicting. Patients and Methods: The CSC antigens CD117/c-KIT, CD133 and breast cancer resistance protein-1 (BCRP1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Herpel, Esther (VerfasserIn) , Jensen, Katrin (VerfasserIn) , Muley, Thomas (VerfasserIn) , Warth, Arne (VerfasserIn) , Schnabel, Philipp Albert (VerfasserIn) , Meister, Michael (VerfasserIn) , Herth, Felix (VerfasserIn) , Dienemann, Hendrik (VerfasserIn) , Thomas, Michael (VerfasserIn) , Gottschling, Sandra (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: [December 2011]
In: Anticancer research
Year: 2011, Jahrgang: 31, Heft: 12, Pages: 4491-4500
ISSN:1791-7530
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://ar.iiarjournals.org/content/31/12/4491
Volltext
Verfasserangaben:Esther Herpel, Katrin Jensen, Thomas Muley, Arne Warth, Philipp A. Schnabel, Michael Meister, Felix J. F. Herth, Hendrik Dienemann, Michael Thomas and Sandra Gottschling
Beschreibung
Zusammenfassung:Background: In various tumor entities, expression of cancer stem cell (CSC) antigens has been proven to be prognostically unfavorable. However, for lung cancer, the data are scant and conflicting. Patients and Methods: The CSC antigens CD117/c-KIT, CD133 and breast cancer resistance protein-1 (BCRP1/ABCG2) were immunohistochemically analyzed in tissues from a total of 133 completely resected stage I/II non-small cell lung cancer (NSCLC) patients with a median follow-up time of 53.8 months. Their expression was related to clinicopathological characteristics, angiogenic features and prognosis. Results: Cox proportional hazards regression analysis revealed no association between CSC antigens, disease-free survival or overall survival (OS). However, in the subgroup of patients with relapse and tumors >3 cm, there was a trend towards worse OS upon expression of CD117 (hazard ratio=2.6, 95%, confidence interval=0.8-8.3, p=0.080). Except for CD133, which was overrepresented in T1 tumors (p=0.001), the CSC antigens were not linked to clinico-pathological characteristics or angiogenic features. Conclusion: In resected early-stage NSCLC, CSC antigens show no association with prognosis. However, in patients with relapse and tumors >3 cm, expression of CD117 might predict worse OS.
Beschreibung:Gesehen am 06.10.2022
Beschreibung:Online Resource
ISSN:1791-7530

Ähnliche Einträge